inhibitor of aldose reductase (AKR1B1). New linkages (ether/triazole/amide) were introduced via high yielding, efficient syntheses to replace the labile ester, and an original two-step (90%) preparation of BGG was developed. Inhibition of AKR1B1was assessed in vitro and using transgenic lens organ cultures, which identified the amide linked glucoside (BGA) as a stable, potent, and selective therapeutic
β-Glucogallin(BGG),所述的主要成分余甘厚朴药用植物,是醛糖还原酶(AKR1B1)的强效的和选择性的
抑制剂。通过高产、高效的合成引入了新的键(醚/三唑/酰胺)以替代不稳定的酯,并开发了 BGG 的原始两步 (90%) 制备。在体外和使用转
基因晶状体器官培养物评估了对 AKR1B1 的抑制作用,发现酰胺连接的
葡萄糖苷 (BGA) 是一种稳定、有效和选择性的治疗糖尿病眼病的先导药物。